These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9043830)

  • 1. Growth hormone in the treatment of heart failure: a new tool for the future?
    Jonkman FA; De Jong G; Fioretti PM
    Eur Heart J; 1997 Feb; 18(2):181-4. PubMed ID: 9043830
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy.
    Osterziel KJ; Strohm O; Schuler J; Friedrich M; Hänlein D; Willenbrock R; Anker SD; Poole-Wilson PA; Ranke MB; Dietz R
    Lancet; 1998 Apr; 351(9111):1233-7. PubMed ID: 9643742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated heart failure in a 74-year-old man with left ventricular hypertrophy.
    Ochi Y; Kubo T; Kitaoka H
    Heart; 2014 May; 100(9):710: discussion 742. PubMed ID: 24711462
    [No Abstract]   [Full Text] [Related]  

  • 4. Candesartan: from left ventricular hypertrophy to heart failure, a global approach.
    Barrios V; Escobar C; Calderon A
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):825-34. PubMed ID: 17867913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating diastolic heart failure: the role of ACE inhibitors.
    Bettencourt P
    Rev Port Cardiol; 1999 Sep; 18 Suppl 5():V101-6. PubMed ID: 10582470
    [No Abstract]   [Full Text] [Related]  

  • 6. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
    Zamani P; Akers S; Soto-Calderon H; Beraun M; Koppula MR; Varakantam S; Rawat D; Shiva-Kumar P; Haines PG; Chittams J; Townsend RR; Witschey WR; Segers P; Chirinos JA
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28219917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should regression or prevention of development of the electrocardiographic strain pattern be an indication for more aggressive treatment in hypertensive patients?
    Okin PM
    J Hypertens; 2010 Aug; 28(8):1617-9. PubMed ID: 20647857
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth hormone as a potential future therapy for congestive heart failure.
    Fazio S; Cittadini A; Biondi B; Palmieri EA; Saccà L
    Coron Artery Dis; 1999 Sep; 10(6):383-8. PubMed ID: 10474788
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth hormone therapy for heart failure: swimming against the stream.
    Saccà L
    J Card Fail; 1999 Sep; 5(3):269-75. PubMed ID: 10496200
    [No Abstract]   [Full Text] [Related]  

  • 10. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview.
    Vasan RS; Levy D
    Arch Intern Med; 1996 Sep; 156(16):1789-96. PubMed ID: 8790072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EFFICACY OF STANDARD TWO-YEAR COMPREHENSIVE THERAPY TO ACHIEVE TARGET BLOOD PRESSURE AND REGRESSION DEGREES OF REMODELING OF THE LEFT VENTRICULAR HYPERTROPHY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION WITH COMORBID HYPERTENSION].
    Denesiuk EV
    Lik Sprava; 2015; (7-8):22-9. PubMed ID: 27491146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure.
    Kato T; Niizuma S; Inuzuka Y; Kawashima T; Okuda J; Tamaki Y; Iwanaga Y; Narazaki M; Matsuda T; Soga T; Kita T; Kimura T; Shioi T
    Circ Heart Fail; 2010 May; 3(3):420-30. PubMed ID: 20176713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic left ventricular hypertrophy in an infant.
    Bhardwaj R; Bhardwaj P
    Indian Heart J; 2011; 63(5):483-4. PubMed ID: 23550435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invited commentary.
    Dixon IM
    Ann Thorac Surg; 2009 Dec; 88(6):1921-2. PubMed ID: 19932263
    [No Abstract]   [Full Text] [Related]  

  • 16. Renin-angiotensin system mediated mechanisms: cardioreparation and cardioprotection.
    Brilla CG
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i18-9:discussion i50. PubMed ID: 10956314
    [No Abstract]   [Full Text] [Related]  

  • 17. Aortic stenosis: from pressure overload to heart failure.
    Carabello BA
    Heart Fail Clin; 2006 Oct; 2(4):435-42. PubMed ID: 17448430
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel mechanism of heart failure with normal ejection fraction.
    Maciver DH; Townsend M
    Heart; 2008 Apr; 94(4):446-9. PubMed ID: 17483129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.
    Valero-Munoz M; Li S; Wilson RM; Boldbaatar B; Iglarz M; Sam F
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 27810862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass.
    Smit JW; Janssen YJ; Lamb HJ; van der Wall EE; Stokkel MP; Viergever E; Biermasz NR; Bax JJ; Vliegen HW; de Roos A; Romijn JA; Roelfsema F
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4638-43. PubMed ID: 11600518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.